Menu
Home
Forums
Forums
Quick Links
Search Forums
Recent Posts
job listings
catering
whistleblower info
legal help
advertise on CP
submit press release
Menu
Log in
Sign up
Search titles only
Posted by Member:
Separate names with a comma.
Newer Than:
Search this thread only
Search this forum only
Display results as threads
More...
Useful Searches
Recent Posts
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
Zimmer
>
Amedica and Zimmer soon to be one
>
Reply to Thread
Name:
Verification:
Answer the above question:
(
CustomImgCaptcha
By
Surrey Forum
)
Message:
<p>[QUOTE="anonymous, post: 6011766"]Talk about yearly guidance...why there is no guidance for 2018 yet??? Still can't figure out how much Amedica tech will help Zimmer to boost up revenue in 2018!</p><p><br /></p><p><b>Full Year 2012 Report</b>:</p><p><br /></p><blockquote><p><b>The Company expects <span style="color: #ff0000">full-year revenues for 2013</span> to increase between 2.5% and 4.5% on a constant currency basis</b>. </p></blockquote><p><br /></p><p><a href="https://www.sec.gov/Archives/edgar/data/1136869/000119312513031002/d475932dex991.htm" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.sec.gov/Archives/edgar/data/1136869/000119312513031002/d475932dex991.htm" rel="nofollow">https://www.sec.gov/Archives/edgar/data/1136869/000119312513031002/d475932dex991.htm</a></p><p><br /></p><p><b>Full Year 2013 Report</b>:</p><p><br /></p><blockquote><p><b>The Company expects <span style="color: #ff0000">full-year revenues for 2014</span> to increase between 3.0% and 5.0% on a constant currency basis</b>. </p></blockquote><p><br /></p><p><a href="https://www.sec.gov/Archives/edgar/data/1136869/000119312514027376/d667348dex991.htm" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.sec.gov/Archives/edgar/data/1136869/000119312514027376/d667348dex991.htm" rel="nofollow">https://www.sec.gov/Archives/edgar/data/1136869/000119312514027376/d667348dex991.htm</a></p><p><br /></p><p><b><span style="color: #ff0000">Full Year 2014 Report, NO FULL YEAR GUIDANCE for 2015</span>:</b></p><p><br /></p><blockquote><p><b><span style="color: #000000">This guidance does not contemplate the projected accretion associated with the </span><span style="color: #ff0000">pending Biomet merger</span><span style="color: #000000">. Guidance for the </span><span style="color: #ff0000">full year 2015</span><span style="color: #000000"> will be provided after the </span><span style="color: #ff0000">closing of the transaction with Biomet</span><span style="color: #000000">, expected before the end of this quarter.</span></b></p></blockquote><p><br /></p><p><a href="https://www.sec.gov/Archives/edgar/data/1136869/000119312515024461/d862570dex991.htm" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.sec.gov/Archives/edgar/data/1136869/000119312515024461/d862570dex991.htm" rel="nofollow">https://www.sec.gov/Archives/edgar/data/1136869/000119312515024461/d862570dex991.htm</a></p><p><br /></p><p><b>Full Year 2015 Report</b>:</p><p><br /></p><blockquote><p><b>The Company expects constant currency <span style="color: #ff0000">revenue for the full year 2016</span>, as compared to adjusted pro forma 2015 revenue, to increase between 1.5% and 2.5%</b>.</p></blockquote><p><br /></p><p><a href="https://www.sec.gov/Archives/edgar/data/1136869/000119312516440674/d95315dex991.htm" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.sec.gov/Archives/edgar/data/1136869/000119312516440674/d95315dex991.htm" rel="nofollow">https://www.sec.gov/Archives/edgar/data/1136869/000119312516440674/d95315dex991.htm</a></p><p><br /></p><p><b>Full Year 2016 Report</b>:</p><p><br /></p><blockquote><p><b>The Company expects constant currency <span style="color: #ff0000">revenue for full-year 2017</span>, as compared to 2016 revenue, to increase between 3.7% and 4.7%</b></p></blockquote><p><br /></p><p><a href="https://www.sec.gov/Archives/edgar/data/1136869/000119312517024528/d338232dex991.htm" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.sec.gov/Archives/edgar/data/1136869/000119312517024528/d338232dex991.htm" rel="nofollow">https://www.sec.gov/Archives/edgar/data/1136869/000119312517024528/d338232dex991.htm</a></p><p><br /></p><p><b><span style="color: #ff0000">Full Year 2017 Report, NO FULL YEAR GUIDANCE FOR 2018, WHY? Only talked about Q1 2018 Guidance (there must be a good reason!):</span></b></p><p><br /></p><p>For the <span style="color: #0080ff">first quarter of 2018</span>, the Company expects revenue in the range of $1.955 billion to $1.995 billion, representing a change of negative 1.0% to positive 1.0% compared to the prior year period, and negative 4.0% to negative 2.0% on a constant currency basis compared to the prior year period, inclusive of negative impact related to approximately one less billing day compared to the prior year period.</p><p><br /></p><p>Additionally, the Company expects its diluted earnings per share for the <span style="color: #0000ff">first quarter of 2018</span> to be in a range of $0.73 to $0.88, and in a range of $1.84 to $1.91 on an adjusted basis.</p><p><br /></p><p><a href="https://www.sec.gov/Archives/edgar/data/1136869/000156459018001032/zbh-ex991_6.htm" target="_blank" class="externalLink ProxyLink" data-proxy-href="https://www.sec.gov/Archives/edgar/data/1136869/000156459018001032/zbh-ex991_6.htm" rel="nofollow">https://www.sec.gov/Archives/edgar/data/1136869/000156459018001032/zbh-ex991_6.htm</a></p><p><br /></p><p>What event was Hanson referring to & hinting the investors? Sounds exciting, isn't it? & what was the hold back on the 2018 Full Year Revenue Guidance disclosure? Why so much misleading information about Amedica by some individuals here? Even create a new alias to post to <b><span style="color: #ff0000">distort the FACT</span></b>! What is cooking between Zimmer & Amedica? How big the transaction will be?</p><p><br /></p><p><b><span style="color: #ff0000">ALL FACT! All SOURCED information with links to verify!</span></b>[/QUOTE]</p><p><br /></p>
[QUOTE="anonymous, post: 6011766"]Talk about yearly guidance...why there is no guidance for 2018 yet??? Still can't figure out how much Amedica tech will help Zimmer to boost up revenue in 2018! [B]Full Year 2012 Report[/B]: [INDENT][B]The Company expects [COLOR=#ff0000]full-year revenues for 2013[/COLOR] to increase between 2.5% and 4.5% on a constant currency basis[/B]. [/INDENT] [URL]https://www.sec.gov/Archives/edgar/data/1136869/000119312513031002/d475932dex991.htm[/URL] [B]Full Year 2013 Report[/B]: [INDENT][B]The Company expects [COLOR=#ff0000]full-year revenues for 2014[/COLOR] to increase between 3.0% and 5.0% on a constant currency basis[/B]. [/INDENT] [URL]https://www.sec.gov/Archives/edgar/data/1136869/000119312514027376/d667348dex991.htm[/URL] [B][COLOR=#ff0000]Full Year 2014 Report, NO FULL YEAR GUIDANCE for 2015[/COLOR]:[/B] [INDENT][B][COLOR=#000000]This guidance does not contemplate the projected accretion associated with the [/COLOR][COLOR=#ff0000]pending Biomet merger[/COLOR][COLOR=#000000]. Guidance for the [/COLOR][COLOR=#ff0000]full year 2015[/COLOR][COLOR=#000000] will be provided after the [/COLOR][COLOR=#ff0000]closing of the transaction with Biomet[/COLOR][COLOR=#000000], expected before the end of this quarter.[/COLOR][/B][/INDENT] [URL]https://www.sec.gov/Archives/edgar/data/1136869/000119312515024461/d862570dex991.htm[/URL] [B]Full Year 2015 Report[/B]: [INDENT][B]The Company expects constant currency [COLOR=#ff0000]revenue for the full year 2016[/COLOR], as compared to adjusted pro forma 2015 revenue, to increase between 1.5% and 2.5%[/B].[/INDENT] [URL]https://www.sec.gov/Archives/edgar/data/1136869/000119312516440674/d95315dex991.htm[/URL] [B]Full Year 2016 Report[/B]: [INDENT][B]The Company expects constant currency [COLOR=#ff0000]revenue for full-year 2017[/COLOR], as compared to 2016 revenue, to increase between 3.7% and 4.7%[/B][/INDENT] [B][/B] [URL]https://www.sec.gov/Archives/edgar/data/1136869/000119312517024528/d338232dex991.htm[/URL] [B][COLOR=#ff0000]Full Year 2017 Report, NO FULL YEAR GUIDANCE FOR 2018, WHY? Only talked about Q1 2018 Guidance (there must be a good reason!):[/COLOR][/B] For the [COLOR=#0080ff]first quarter of 2018[/COLOR], the Company expects revenue in the range of $1.955 billion to $1.995 billion, representing a change of negative 1.0% to positive 1.0% compared to the prior year period, and negative 4.0% to negative 2.0% on a constant currency basis compared to the prior year period, inclusive of negative impact related to approximately one less billing day compared to the prior year period. Additionally, the Company expects its diluted earnings per share for the [COLOR=#0000ff]first quarter of 2018[/COLOR] to be in a range of $0.73 to $0.88, and in a range of $1.84 to $1.91 on an adjusted basis. [URL]https://www.sec.gov/Archives/edgar/data/1136869/000156459018001032/zbh-ex991_6.htm[/URL] What event was Hanson referring to & hinting the investors? Sounds exciting, isn't it? & what was the hold back on the 2018 Full Year Revenue Guidance disclosure? Why so much misleading information about Amedica by some individuals here? Even create a new alias to post to [B][COLOR=#ff0000]distort the FACT[/COLOR][/B]! What is cooking between Zimmer & Amedica? How big the transaction will be? [B][COLOR=#ff0000]ALL FACT! All SOURCED information with links to verify![/COLOR][/B][/QUOTE]
Your name or email address:
Do you already have an account?
No, create an account now.
Yes, my password is:
Forgot your password?
Stay logged in
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
Zimmer
>
Amedica and Zimmer soon to be one
>
Cafepharma Message Boards | Pharma Sales, Device Sales, Lab Sales
Home
Forums
>
Medical Equipment/Device Sales
>
Zimmer
>
Amedica and Zimmer soon to be one
>